MMIT Reality Check on Hereditary Angioedema (2Q2023)

Payer Coverage:

A review of market access for hereditary angioedema treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered with utilization management restrictions. Around 34% of the lives under Medicare formularies are not covered for at least one of the drugs.

Under the medical benefit, about 66% of the lives under commercial policies are covered with utilization management restrictions. Almost 68% of the lives under Medicare policies have access to at least one of the drugs without utilization management restrictions.

For about 89% of the covered lives, payer pharmacy benefit formularies do not require step therapy (ST). Of the lives that require ST, about 8% require multiple steps. Around 82% of payer-controlled pharmacy benefit covered lives require prior authorization.

Trends:

FDA Expands Patient Population for Takhzyro

In February 2023, the FDA expanded the patient population for Takeda’s Takhzyro (lanadelumab-flyo) to include the prevention of hereditary angioedema attacks in people at least 2 years old. The agency initially approved the plasma kallikrein inhibitor on Aug. 3, 2018. Dosing of the subcutaneous injectable in people at least 12 years old is 300 mg every two weeks. In people at least 6 and less than 12, dosing is 150 mg every two weeks, and for people 2 years old and younger than 6, dosing is 150 mg every four weeks. Drugs.com lists the price of one single-dose 300 mg/2 mL subcutaneous solution as more than $26,165.

Cycle Pharmaceuticals Launches Sajazir

In September 2021, Cycle Pharmaceuticals launched Sajazir (icatibant) for the treatment of acute hereditary angioedema attacks in people at least 18 years old. It is a generic version of Takeda Pharmaceuticals U.S.A., Inc.’s Firazyr.

FDA Approves First Oral Therapy For Prevention of HAE Attacks

When the FDA approved BioCryst Pharmaceuticals, Inc.’s Orladeyo (berotralstat), the drug became the first oral treatment for prophylaxis to prevent hereditary angioedema (HAE) attacks. According to Zitter Insights, payers with nearly three-quarters of covered lives plan to manage it at parity to other prophylactic treatments.

HAE is a rare but potentially fatal condition that causes swelling in various parts of the body, including the hands, feet, intestinal tract, face, larynx and trachea.

Key Findings:

Market Events Drive Changes

There are currently multiple products approved by the FDA for preventing and treating hereditary angioedema (HAE) attacks, including numerous generic versions of Takeda Pharmaceuticals U.S.A., Inc.’s Firazyr. In February 2023, the FDA expanded the patient population for Takeda’s Takhzyro (lanadelumab-flyo) to include the prevention of hereditary angioedema attacks in people at least 2 years old. In December 2020, the agency approved BioCryst Pharmaceuticals, Inc.’s Orladeyo (berotralstat) for prophylaxis to prevent HAE attacks in people at least 12 years old. It is the first oral treatment approved for this use.

Competitive Market Landscape

Health plans don’t differentiate coverage among provider-administered products, and access to HAE products is not limited at the brand level. However, increased competition is expected as more prophylactic therapies enter the market. As contract negotiations continue to drive to preferred products, step therapy will become more prevalent.

Pharmacy, Medical Benefit Implications

Coverage is under both the pharmacy and medical benefits. Self-administered products are usually covered under the pharmacy benefit. Drugs for this indication are generally covered with prior authorization (PA). When PA is defined, diagnosis of HAE is confirmed by C4 and C1-INH levels below normal as defined by the laboratory performing the test. A history of HAE attacks is required. There is minimal step restriction with the exception of Cinryze, which most policies will require a step through a generic alternative prophylaxis.

Key Players in Market:

reality-check-hae-player

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

May 5

MMIT Reality Check on Anemia Due to Chronic Kidney Disease (2Q2023)

Read More
a-doctor-interviewing-a-patient
June 2

MMIT Reality Check on Cervical Cancer (2Q2023)

Read More
growth-hormone-deficiency
April 28

MMIT Reality Check on Growth Hormone Deficiency (2Q2023)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today